JP2024521767A5 - - Google Patents
Info
- Publication number
- JP2024521767A5 JP2024521767A5 JP2023572717A JP2023572717A JP2024521767A5 JP 2024521767 A5 JP2024521767 A5 JP 2024521767A5 JP 2023572717 A JP2023572717 A JP 2023572717A JP 2023572717 A JP2023572717 A JP 2023572717A JP 2024521767 A5 JP2024521767 A5 JP 2024521767A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition according
- disease
- complement
- amd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2107586.6A GB202107586D0 (en) | 2021-05-27 | 2021-05-27 | Inhibitory nucleic acids for Factor H family proteins |
| GB2107586.6 | 2021-05-27 | ||
| PCT/EP2022/064376 WO2022248651A2 (en) | 2021-05-27 | 2022-05-26 | Inhibitory nucleic acids for factor h family proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521767A JP2024521767A (ja) | 2024-06-04 |
| JP2024521767A5 true JP2024521767A5 (cg-RX-API-DMAC10.html) | 2025-06-03 |
Family
ID=76741290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572717A Pending JP2024521767A (ja) | 2021-05-27 | 2022-05-26 | Ｈ因子ファミリータンパク質のための阻害性核酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240209367A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4347030A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024521767A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118632711A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022279580A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3219247A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB202107586D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022248651A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024218976A1 (en) * | 2023-02-06 | 2025-09-11 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2026101913A1 (en) * | 2024-11-05 | 2026-05-15 | Alnylam Pharmaceuticals, Inc. | Sirnas targeting complement factor h-related (cfhr) gene transcripts and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20050118625A1 (en) * | 2003-10-02 | 2005-06-02 | Mounts William M. | Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| US7745389B2 (en) | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
| DK2447275T3 (en) * | 2006-07-13 | 2015-06-29 | Univ Iowa Res Found | Methods and reagents for the treatment of age-related macular degeneration |
| WO2009059317A2 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| US9598733B2 (en) | 2011-02-17 | 2017-03-21 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing IgA nephropathy |
| WO2013151192A1 (ko) | 2012-04-02 | 2013-10-10 | 주식회사 성균바이오텍 | 등골나물속 추출물을 유효성분으로 하는 비만 및 골대사질환 예방 및 치료용 조성물 |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| GB201709222D0 (en) | 2017-06-09 | 2017-07-26 | Univ Manchester | C3b Inactivating Polypeptide |
| JP2020533414A (ja) * | 2017-09-11 | 2020-11-19 | インサイドアウトバイオ インコーポレイテッド | 腫瘍の免疫原性を増強する方法および組成物 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| JP7467355B2 (ja) | 2018-05-10 | 2024-04-15 | コンプリメント・セラピューティクス・リミテッド | 黄斑変性症を評価するための方法 |
| EP4214515A1 (en) | 2020-09-16 | 2023-07-26 | Complement Therapeutics Limited | Complementome assay |
-
2021
- 2021-05-27 GB GBGB2107586.6A patent/GB202107586D0/en not_active Ceased
-
2022
- 2022-05-26 AU AU2022279580A patent/AU2022279580A1/en active Pending
- 2022-05-26 WO PCT/EP2022/064376 patent/WO2022248651A2/en not_active Ceased
- 2022-05-26 EP EP22731536.3A patent/EP4347030A2/en active Pending
- 2022-05-26 JP JP2023572717A patent/JP2024521767A/ja active Pending
- 2022-05-26 CA CA3219247A patent/CA3219247A1/en active Pending
- 2022-05-26 CN CN202280038270.4A patent/CN118632711A/zh active Pending
-
2023
- 2023-11-27 US US18/519,153 patent/US20240209367A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7687685B2 (ja) | 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド | |
| JP7661228B2 (ja) | オリゴヌクレオチド組成物及びその方法 | |
| JP7406793B2 (ja) | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 | |
| JP7564125B2 (ja) | スプライシング及び翻訳を調節するための方法及び組成物 | |
| JP2010500025A5 (cg-RX-API-DMAC10.html) | ||
| US20190161755A1 (en) | Compositions and methods for inhibiting factor d | |
| US20190167811A1 (en) | Lipid compositions and their uses for intratumoral polynucleotide delivery | |
| US20250354148A1 (en) | DUAL-ACTING siRNA BASED MODULATION OF C9orf72 | |
| JP2020105205A (ja) | トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療方法 | |
| US11814622B2 (en) | OPA1 antisense oligomers for treatment of conditions and diseases | |
| WO2008021136B1 (en) | Methods and sequences to suppress primate huntington gene expression in vivo | |
| CN108291225A (zh) | 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途 | |
| US20150141320A1 (en) | Compositions and methods for modulating gene expression | |
| JP2022544702A (ja) | スプライシングおよびタンパク質発現を調節するための組成物および方法 | |
| EP3708184A1 (en) | Methods and agents for treating alzheimer s disease | |
| JP7660515B2 (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| US20250059535A1 (en) | Opa1 antisense oligomers for treatment of conditions and diseases | |
| EP3122365B1 (en) | Transthyretin allele selective una oligomers for gene silencing | |
| JP2021523369A5 (cg-RX-API-DMAC10.html) | ||
| JP2023524130A5 (cg-RX-API-DMAC10.html) | ||
| CN119403926A (zh) | 用于减少富亮氨酸重复激酶2（lrrk2）的表达的寡核苷酸及其用于预防和/或治疗人类疾病的用途 | |
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| US20230304012A1 (en) | Muscle regeneration and growth | |
| JP2024524974A (ja) | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー | |
| CN102028947B (zh) | Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途 |